Sam Brusco, Associate Editor04.29.22
Abbott launched its Amplatzer steerable delivery sheath in the U.S. yesterday. It’s used with the firm’s Amplatzer Amulet left atrial appendage (LAA) occluder to treat those with atrial fibrillation (AFib) at risk of ischemic stroke.
Patients with AFib who are unable to take blood-thinning medication long term may opt for a minimally invasive procedure using tech like Amulet to seal off the LAA entirely and reduce stroke risk.
"Since its FDA clearance last year, doctors have been utilizing Abbott's Amulet device to help patients reduce their risk of stroke from atrial fibrillation without the need for blood-thinning medication," Vivek Y. Reddy, M.D., director of electrophysiology, Mount Sinai Hospital, who completed the first U.S. procedure with the delivery system, told the press. "With the Amplatzer Steerable Delivery Sheath, U.S. physicians now have more flexibility and precise placement when implanting the Amulet device, in simple and complex anatomies. It allows doctors to close left atrial appendages in challenging cases, when otherwise it might not be possible."
Amplatzer Amulet with dual-seal technology (consisting of a lobe or piece to fill the LAA cavity and a disc to close off the opening into the LAA) offers immediate and complete LAA closure. The newly launched steerable delivery sheath combines bi-directional steering and auto-lock functions to help the sheath stay in its desired position. The delivery system also includes a valve to stabilize blood flow and minimize blood loss during the procedure.
"The Amulet LAA occluder and Amplatzer steerable delivery sheath are examples of Abbott's commitment to helping people with structural heart diseases live their best lives, and we remain committed to the continued innovation of our technology for the benefit of physicians and patients worldwide," said Michael Dale, senior VP of Abbott's structural heart business. "Abbott is focused on advancing technology for LAA occlusion devices as well as how they are delivered to optimize the physician experience and improve outcomes for patients."
Patients with AFib who are unable to take blood-thinning medication long term may opt for a minimally invasive procedure using tech like Amulet to seal off the LAA entirely and reduce stroke risk.
"Since its FDA clearance last year, doctors have been utilizing Abbott's Amulet device to help patients reduce their risk of stroke from atrial fibrillation without the need for blood-thinning medication," Vivek Y. Reddy, M.D., director of electrophysiology, Mount Sinai Hospital, who completed the first U.S. procedure with the delivery system, told the press. "With the Amplatzer Steerable Delivery Sheath, U.S. physicians now have more flexibility and precise placement when implanting the Amulet device, in simple and complex anatomies. It allows doctors to close left atrial appendages in challenging cases, when otherwise it might not be possible."
Amplatzer Amulet with dual-seal technology (consisting of a lobe or piece to fill the LAA cavity and a disc to close off the opening into the LAA) offers immediate and complete LAA closure. The newly launched steerable delivery sheath combines bi-directional steering and auto-lock functions to help the sheath stay in its desired position. The delivery system also includes a valve to stabilize blood flow and minimize blood loss during the procedure.
"The Amulet LAA occluder and Amplatzer steerable delivery sheath are examples of Abbott's commitment to helping people with structural heart diseases live their best lives, and we remain committed to the continued innovation of our technology for the benefit of physicians and patients worldwide," said Michael Dale, senior VP of Abbott's structural heart business. "Abbott is focused on advancing technology for LAA occlusion devices as well as how they are delivered to optimize the physician experience and improve outcomes for patients."